MODERNA News & Analysis

We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.

We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.

Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.

The plasma giant remains overvalued, according to Morningstar.

Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?